# Saladax Biomedical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/saladax-biomedical

- Industry: Biotechnology
- Headquarters: Bethlehem, US
- Website: www.saladax.com
- Total disclosed funding: $12M
- Latest round: Series C (Mar 5, 2010)
- Investors on record: 7

## About

Saladax Biomedical develops and manufactures therapeutic drug monitoring (TDM) assays to optimize the dosing of life-saving medications in psychiatric and oncological applications.Founded in 2004, Saladax Biomedical is based in Bethlehem, US, and focuses on therapeutic drug monitoring solutions. The company was established by Salvatore Salamone, who has a history of entrepreneurial ventures. Saladax Biomedical has raised a total of USD 22.40 mn across multiple funding rounds, with the most recent being a VENTURE DEBT round in July 2013, securing USD 8.00 mn from GE Capital Healthcare Financial Services.Saladax Biomedical specializes in the development and manufacturing of therapeutic drug monitoring (TDM) assays, primarily designed for life-saving medications prescribed in psychiatric and oncological settings. Their core product offerings focus on ensuring that patients receive optimal dosing of essential drugs, particularly clozapine, through precise measurement of drug levels in the blood. These assays are critical for personalizing treatment plans and improving patient outcomes by allowing healthcare professionals to adjust dosages in real-time based on individual patient responses. Saladax's products serve a diverse client base, including psychiatrists and oncologists, as well as laboratories and healthcare facilities that prioritize personalized medicine. Saladax's products are utilized in various international markets, including regions in Europe and other parts of the world where personalized pharmacotherapy is gaining traction.Saladax Biomedical operates on a business-to-business model, generating revenue primarily through sales of their TDM assays to healthcare providers and laboratories. Transactions typically involve direct purchases of their assay products, which may be complemented by training or support services for healthcare professionals to ensure effective implementation of the assays in clinical settings. Partnerships with distributors, such as Katalyst Diagnostics, enhance market access and distribution efficiency. The pricing structure for Saladax's flagship products, including the MyCare™ Insite monitoring system, reflects the value of improved patient outcomes through personalized treatment solutions, reinforcing the importance of TDM in psychiatric and oncology practices.Saladax Biomedical plans to leverage the recent VENTURE DEBT financing of USD 8.00 mn to support the development and launch of new therapeutic drug monitoring products. The company is targeting expansion into European markets, aiming for increased accessibility and utilization of its assays by 2025. Recent funding will be directed towards enhancing product development and bolstering marketing efforts to establish a stronger presence in new regions.

## Funding rounds

- Series C, Mar 5, 2010, $8.4M — Ben Franklin Technology Partners, Excel Venture Management, Golden Seeds, Life Sciences Greenhouse of Central Pennsylvania
- Series A, Aug 25, 2008, $3.6M — Pittsburgh Life Sciences Greenhouse, Columbia Ventures Corporation
- Series B, Dec 12, 2007, $0.3M — Golden Seeds, Delaware Crossing Investor Group

## Investors

- Golden Seeds (https://capitalatlas.ai/funds/golden-seeds) — Series B, Series C
- Delaware Crossing Investor Group — Series B
- Pittsburgh Life Sciences Greenhouse (https://capitalatlas.ai/funds/pittsburgh-life-sciences-greenhouse) — Series A
- Columbia Ventures Corporation — Series A
- Ben Franklin Technology Partners (https://capitalatlas.ai/funds/ben-franklin-technology-partners) — Series C
- Excel Venture Management (https://capitalatlas.ai/funds/excel-venture-management) — Series C
- Life Sciences Greenhouse of Central Pennsylvania — Series C